Candel Therapeutics

Candel Therapeutics(CADL)

NEEDHAM, MA
Biotechnology3 H-1B visas (FY2023)

Focus: Oncolytic Viral Immunotherapies for Cancer

Candel Therapeutics is a life sciences company focused on Oncolytic Viral Immunotherapies for Cancer.

Oncology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

CAN-2409 + valacyclovir
Lung Cancer
Phase 1
Clinical Trials (1)
NCT03131037Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
Phase 1
Clinical Trials (1)
NCT03152318A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Phase 1
Clinical Trials (1)
NCT00638612AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT00634231A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT00751270Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Phase 1
AdV-tk + valacyclovir
Malignant Pleural Effusion
Phase 1
Clinical Trials (1)
NCT01997190Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Phase 1
Clinical Trials (1)
NCT02446093Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Phase 2
aglatimagene besadenovec + valacyclovir
Prostate Cancer Patients Treated by Radiotherapy
Phase 2
Clinical Trials (1)
NCT07332000A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Phase 2
aglatimagene besadenovec
Prostate Cancer
Phase 2
Clinical Trials (1)
NCT02768363Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Phase 2
Phase 2
Clinical Trials (1)
NCT00589875Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Phase 2
Aglatimagene besadenovec
Non Small Cell Lung Cancer
Phase 2
Clinical Trials (1)
NCT04495153CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Phase 2
Aglatimagene besadenovec + valacyclovir
Prostate Cancer
Phase 3
Clinical Trials (1)
NCT01436968Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 12 clinical trials
H-1B (2023): 3 approvals
SEC Filings: 2 available

Financials (FY2025)

R&D Spend
$19M21%
Net Income
-$55M
Cash
$103M

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
3
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub